Evogene LtdEVGN
Price$0.44

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $3.9M-30.9% YoYTTM through 31 Dec 2025
Net Income -$7.8MTTM through 31 Dec 2025
Free Cash Flow -$13.6MTTM through 31 Dec 2025

Margins

Current
Gross Margin61.1%
EBITDA Margin-350.7%
Operating Margin-943.1%
Net Margin-203.1%

Returns

-73.8%ROE
-32.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.79x
Net Debt-$13.1Mnet cash position
Cash & Equivalents$13M

Quality Metrics

Piotroski F-Score3 / 9
FCF Margin-353.9%
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $3.9M
Diluted EPS
'19'20'21'22'23'24'25
FY2025: $-0.99

Dividend

No dividend

Capital Allocation

Capex Intensity3.5%

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.